Lupus Therapeutic Market, By Disease Type (Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), By Treatment Type, By Route of Administration, By Distribution Channel, By Geography

PUBLISHED: May 31, 2024

PAGES: 167 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global lupus therapeutic market is estimated to be valued at USD 3.25 Bn in 2024 and is expected to reach USD 5.91 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Figure 1. Lupus Therapeutic Market Share (%), By Region, 2024

The global lupus therapeutic market has been witnessing steady growth over the past few years owing to the rising prevalence of lupus disease globally. Lupus is a chronic autoimmune disorder where the immune system of the body starts attacking its own tissues and organs. It commonly affects women in their childbearing years and major symptoms include joint pain, rashes, fatigue, and organ inflammation. According to estimates, about 1.5 million Americans and at least 5 million people worldwide suffer from a form of lupus. Growing awareness initiatives by government and healthcare organizations regarding early diagnosis and treatment of lupus has further boosted the market growth. Moreover, ongoing research into developing safer and more effective therapeutic drugs will continue driving the market growth during the forecast period.

Market Dynamics:

The global lupus therapeutic market is driven by the growing prevalence of lupus globally, rising awareness initiatives regarding the disease, and increasing healthcare expenditure. As per the Lupus Foundation of America, around 16,000 new cases are reported in the U.S. every year. Favorable government support for research and development activities focused on lupus therapeutics is also propelling the market growth. However, high treatment cost and lack of drugs for organ-specific lupus are some of the key factors expected to restrain the market growth to a certain extent. On the other hand, ongoing clinical trials for novel biologic drugs and personalized medicine offer lucrative opportunities for market players in the coming years.

Key Features of the Study:

This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global lupus therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this includes Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global lupus therapeutic market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market.

Detailed Segmentation-

By Disease Type:
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
By Treatment Type:
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others
By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
- Others
By Distribution Channel:
- Hospital Pharmacies
- Medical Stores
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Hikma Pharmaceuticals PLC
- Reddy's Laboratories Ltd.
- Amgen Inc.
- Novartis AG
- Sanofi
- UCB S.A.
- ImmuPharma PLC
- Bayer AG
- Merck & Co., Inc.
- Aurinia Pharmaceuticals Inc.
- Pfizer Inc.
- AstraZeneca
- Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International Gmbh

Product Code: CMI4958

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Treatment Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Epidemiology
Market Trends
Key Developments
Regulatory Scenario
Manufacturer Revenue
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Lupus Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Lupus Therapeutic Market, By Disease Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Systemic Lupus Erythematosus (SLE)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cutaneous Lupus Erythematosus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Drug-Induced Lupus Erythematosus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Neonatal Lupus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Lupus Therapeutic Market, By Treatment Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Biologics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Antimalarial Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Lupus Therapeutic Market, By Route of Administration, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Subcutaneous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Lupus Therapeutic Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Medical Stores
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Lupus Therapeutic Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
Middle East

10. Competitive Landscape

Company Profiles
- Hikma Pharmaceuticals PLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Amgen Inc.
- Novartis AG
- Sanofi
- UCB S.A.
- ImmuPharma PLC
- Bayer AG
- Merck & Co., Inc.
- Aurinia Pharmaceuticals Inc.
- Pfizer Inc.
- AstraZeneca
- F.Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International Gmbh